Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial
- 4 May 2007
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 133 (9) , 653-661
Abstract
Relapsed high-risk neuroblastoma patients still have a poor prognosis. This phase-II trial assessed a new topotecan containing chemotherapy approach in patients with active disease. Chemotherapy consisted of topotecan (1.0 mg/m2/day 168-h continuous infusion), cyclophosphamide (100 mg/m2/day 1-h-infusion days 1–7 starting 6 h prior to topotecan), and etoposide (100 mg/m2/day 1-h-infusion days 8–10). Patients with relapsed neuroblastoma were scheduled for six cycles, untreated patients for two cycles followed by standard high-risk treatment. Main toxicity observed during 153 cycles were grade 3–4 leukopenia (97% of cycles), thrombocytopenia (92%), neutropenic fever (52%), and mucositis (10%). No treatment related fatal toxicity occurred. Complete or partial response was achieved in 19 of 31 (61%) evaluable relapsed patients and 8 of 11 (72%) untreated patients. The combination of topotecan, cyclophosphamide, and etoposide is tolerable and effective in relapsed and untreated neuroblastoma. Myelotoxicity is the main side effect but seems justified in view of the encouraging response rates. A randomized phase-III trial in primary disease has been commenced.Keywords
This publication has 50 references indexed in Scilit:
- Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group StudyJournal of Clinical Oncology, 2004
- A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastomaCancer, 2003
- A Phase I–II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinomaCancer, 2002
- Phase II Evaluation of 3-Day Topotecan with Cyclophosphamide in the Treatment of Recurrent Ovarian CancerGynecologic Oncology, 2002
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid TumorsJournal of Pediatric Hematology/Oncology, 1996
- DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitorsMutation Research/DNA Repair, 1995
- Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude miceInternational Journal of Cancer, 1992
- Nonproductive Rearrangement of DNA Topoisomerase I and II Genes: Correlation With Resistance to Topoisomerase InhibitorsJNCI: Journal of the National Cancer Institute, 1989
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989